Martin Shkreli’s notorious brilliance in pumping up the price of Daraprim, an antiparasitic drug, by 5,000% had earned him the sobriquet – The most hated CEO – in 2015.
Now, after three years, Shkreli aka “Pharma Bro” is staring at a decade-long sentence after being convicted in an unrelated case. Karma is like a boomerang, or so they say!
Shkreli is accused of misleading his investors about two of his failed hedge funds, and is held responsible for causing losses of around $10.4 million. Shkreli hid the losses from his investors, started the drug company Retrophin and then used its assets to pay them back. He even made a profit. But the prosecution argued that Shkreli did not deserve credit for this repayment because he made risky investments without the knowledge or permission of his investors using their money.
This ruling comes as a blow to the defense lawyers who were pushing for a lighter sentence.
The court rejected the defense’s argument that there was no loss as the investors had gotten back their money along with some more. The judge pointed out that by the time Shkreli had started to move the money from Retrophin to his hedge fund, the fraud had already been spotted.
The sentence, which could go up to 20 years of imprisonment, is set for March 9.
Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew
Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter
Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings